CRISPR Therapeutics AG (CRSP) Insider Trading -- Recent Executive & Director Transactions

7 insiders reported 64 Form 4 transactions for CRISPR Therapeutics AG (CRSP) over the past 18 months (most recent 2026-09-24). Recent activity: KASINGER JAMES R. (General Counsel and Secretary) Buy 10,400 shares, KASINGER JAMES R. (General Counsel and Secretary) Sell 10,400 shares, Behbahani Ali (Director) Buy 60 shares, Behbahani Ali (Director) Buy 30,000 shares, Behbahani Ali (Director) Buy 15 shares. Source: SEC Form 4.

DateInsiderTitleTypeSharesValue
2026-09-24KASINGER JAMES R.General Counsel and SecretaryBuy10,400$141,648
2026-09-24KASINGER JAMES R.General Counsel and SecretarySell10,400$626,460
2026-09-21Behbahani AliDirectorBuy60$0
2026-09-21Behbahani AliDirectorBuy30,000$420,000
2026-09-21Behbahani AliDirectorBuy15$0
2026-09-21Behbahani AliDirectorSell13,679$780,935
2026-08-11Prasad RajuChief Financial OfficerSell750$0
2026-06-01Patel NaimishChief Medical OfficerBuy10,000$0
2026-06-01Patel NaimishChief Medical OfficerSell3,786$210,577
2026-03-24Prasad RajuChief Financial OfficerSell3,708$173,460
2026-03-24KASINGER JAMES R.General Counsel and SecretarySell3,182$148,854
2026-03-24Prasad RajuChief Financial OfficerBuy6,250$0
2026-03-24KASINGER JAMES R.General Counsel and SecretaryBuy6,250$0
2026-03-24Kulkarni SamarthChief Executive OfficerBuy19,687$0
2026-03-24Kulkarni SamarthChief Executive OfficerSell10,020$468,736
2026-03-17KASINGER JAMES R.General Counsel and SecretaryBuy6,875$0
2026-03-17KASINGER JAMES R.General Counsel and SecretarySell3,450$166,497
2026-03-17Prasad RajuChief Financial OfficerBuy10,000$0
2026-03-17Prasad RajuChief Financial OfficerBuy6,875$0
2026-03-17Prasad RajuChief Financial OfficerSell5,848$282,224
2026-03-17Prasad RajuChief Financial OfficerSell4,021$194,053
2026-03-17Prasad RajuChief Financial OfficerSell750$0
2026-03-17Kulkarni SamarthChief Executive OfficerBuy20,625$0
2026-03-17Kulkarni SamarthChief Executive OfficerSell10,349$499,443
2026-03-17Patel NaimishChief Medical OfficerBuy8,125$0

Source: SEC Form 4 filings · as of 2026-09-24